Cargando…
Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
When designing a comparative oncology trial for an overall or progression-free survival endpoint, investigators often quantify the treatment effect using a difference in median survival times. However, rather than directly designing the study to estimate this difference, it is almost always converte...
Autores principales: | McCaw, Zachary R, Kim, Dae Hyun, Wei, Lee-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877166/ https://www.ncbi.nlm.nih.gov/pubmed/35699499 http://dx.doi.org/10.1093/jncics/pkac007 |
Ejemplares similares
-
Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study
por: Sun, Ryan, et al.
Publicado: (2021) -
Sample size calculation for randomized selection trials with a time‐to‐event endpoint and a margin of practical equivalence
por: Dehbi, Hakim‐Moulay, et al.
Publicado: (2022) -
Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
por: Uno, Hajime, et al.
Publicado: (2019) -
Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19
por: McCaw, Zachary R., et al.
Publicado: (2020) -
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)